«Худая» кошка с хронической болезнью почек Джессика M. Куимби

53

26 мин.

Для просмотра материала полностью, пожалуйста, зарегистрируйтесь или авторизуйтесь на портале
Дата публикации: 13 января 2020
Джессика М. Куимби,
DVM, PhD, дипл. ACVIM,
Университет штата Огайо, Колумбус, штат Огайо, США.
Доктор Куимби получила ученую степень по ветеринарии в Висконсинском университете в Мэдисоне в 2003 г., после чего прошла чередующуюся интернатуру по ветеринарной медицине мелких животных в Калифорнии. Затем она проработала два года в частной клинике для кошек, прошла резидентуру по ветеринарной медицине внутренних болезней мелких животных и получила степень PhD в Колорадском университете. Особенно интересуется заболеваниями почек у кошек и недавно получила должность доцента в Центре ветеринарной медицины Университета штата Огайо.
 

ЛИТЕРАТУРА

 

1. Freeman L, Lachaud MP, Matthews S,et al. Evaluation of weight loss over time in cats with chronic kidney disease. J Vet Intern Med 2015;29:1272.
2. Markovich JE, Freeman LM, Labato MA, et al. Survey of dietary and medication practices of owners of cats with chronic kidney disease. J Feline Med Surg 2015;17:979-983.
3. Freeman LM. Cachexia and sarcopenia: emerging syndromes of importance in dogs and cats. J Vet Intern Med 2012;26:3-17.
4. Argiles JM, Busquets S, Stemmler B, et al. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol 2015;22:100-106.
5. Gunta SS, Mak RH. Ghrelin and leptin pathophysiology in chronic kidney disease. Pediatr Nephrol 2013;28:611-616.
6. Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM).J Renal Nutr 2013;23:77-90.
7. Neyra R, Chen KY, Sun M, et al. Increased resting energy expenditure in patients with end-stage renal disease. J Parenter Enteral Nutr 2003;27:36-42.
8. Laflamme DP. Nutrition for aging cats and dogs and the importance of body condition. Vet Clin North Am Small Anim Pract 2005;35:713-742.
9. Sparkes AH. Feeding old cats – an update on new nutritional therapies. Top Companion Anim Med 2011;26:37-42.
10.Bijsmans ES, Jepson RE, Syme HM, et al. Psychometric validation of a general health quality of life tool for cats used to compare healthy cats and cats with chronic kidney disease. J Vet Intern Med 2016;30:183-191.
11. Goldstein RE, Marks SL, Kass PH, et al. Gastrin concentrations in plasma of cats with chronic renal failure. J Am Vet Med Assoc 1998;213:826-828.
12. McLeland SM, Lunn KF, Duncan CG, et al. Relationship among serum creatinine, serum gastrin, calcium-phosphorus product, and uremic gastropathy in cats with chronic kidney disease. J Vet Intern Med 2014;28:827-837.
13. Borison HL, Hebertson LM. Role of medullary emetic chemoreceptor trigger zone (CT zone) in postnephrectomy vomiting in dogs. Am J Physiol 1959;197:850-852.
14. Ross SJ, Osborne CA, Kirk CA, et al. Clinical evaluation of dietary modification for treatment of spontaneous chronic kidney disease in cats. J Am Vet Med Assoc 2006;229:949-957.
15.Ross S. Utilization of feeding tubes in the management of feline chronic kidney
disease. Vet Clin North Am Small Anim Pract 2016;46:1099-1114.
16. Hickman MA, Cox SR, Mahabir S, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 2008;31:220 229.
17. Quimby JM, Brock WT, Moses K, et al. Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded placebo-controlled clinical trial. J Feline Med Surg 2015;17:692-697.
18. Quimby JM, Lake RC, Hansen RJ, et al. Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. J Vet Pharmacol Ther 2014;37:348-353.
19.Zajic LB, Herndon A, Sieberg L, et al. Investigation of the pharmacokinetics of transdermal ondansetron in normal purpose-bred cats. J Feline Med Surg 2017. Jan 1. 
20. Herndon A, Sieberg L, Davis L, et al. Pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in purpose-bred cats. J Vet Intern Med 2016;30:90.
21. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.Eur J Cancer Care (Engl) 2007;16:351-354.
22.Quimby JM, Lunn KF. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet J 2013;197:651-655.
23. Quimby JM, Gustafson DL, Lunn KF. The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. J Vet Intern Med 2011;25:985-989.
24. Quimby JM, Gustafson DL, Samber BJ, et al. Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats. J Vet Pharmacol Ther 2011;34:388-396.
25. Ferguson LE, McLean MK, Bates JA, et al. Mirtazapine toxicity in cats:
retrospective study of 84 cases (2006-2011). J Feline Med Surg2015.
26. Zollers B, Allen J, Kennedy C, et al. Capromorelin, an orally active ghrelin agonist, caused sustained increases in IGF-1, increased food intake and body weight in cats. J Vet Intern Med 2015;29:1219.
27. Parkinson S, Tolbert K, Messenger K, et al. Evaluation of the effect of orally administered acid suppressants on intragastric pH in cats. J Vet Intern Med 2015;29:104-112.
28. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;176:238-246.
 
 
а
а